{"a":[{"_":"EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu ","$":{"href":"/pharma/eyepoint-shares-plummet-amid-phase-3-stumble-amd-drug-device-combo-duravyu","hreflang":"en"}}]}
Phase 3negativeDuravyuNegative
AI Analysis
Summary
EyePoint Pharmaceuticals' phase 3 trial for Duravyu, a drug-device combination for wet AMD, has failed to meet expectations, resulting in significant stock decline. The setback jeopardizes the company's strategy to compete with Eylea and raises concerns about the upcoming Lucia trial readout scheduled for fall 2026.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial failure for Duravyu drug-device combo
Importance:8/10
Sentiment:
-0.85
ophthalmologyAMDdrug-device combinationclinical trial failureshare price decline
Related Companies
Read the original article
Published by FiercePharma on August 17, 2026 2:59 PM